Evidence-Based Summary
Sermorelin is the 29-amino-acid active fragment of human GHRH. FDA approved it as Geref (1990 for a pituitary test; 1997 for growth failure in children with GH deficiency); EMD Serono discontinued it in 2008, and FDA found the withdrawal was not for safety or effectiveness reasons. CJC-1295 is a modified GHRH analogue that binds to albumin in the blood, so a single injection raised GH and IGF-1 for days in healthy adults (estimated half-life about 6 to 8 days). CJC-1295 was never approved: its Phase 2 trial in people with HIV and abdominal fat is listed as terminated, with no reason given in the registry, and FDA now lists it among compounding substances that may present significant safety risks, citing increased heart rate and systemic vasodilatory reactions. Sermorelin has 1990s pediatric trial data; CJC-1295 has only short studies in healthy volunteers. No trial has compared them, neither is proven to slow aging, and both are banned in sport (WADA S2).
Quick Comparison: Sermorelin vs CJC-1295
A high-level comparison of molecule class, molecular receptor targets, FDA regulatory approvals, and verified clinical programs.
| Feature | Sermorelin | CJC-1295 |
|---|---|---|
| Class | GHRH(1-29) amide: the active fragment of natural GHRH | Modified GHRH analogue that binds blood albumin |
| Target receptor | GHRH receptor on pituitary somatotroph cells | GHRH receptor on pituitary somatotroph cells |
| Duration of action | Short-acting | Long-acting: GH and IGF-1 raised for days after one injection; half-life about 6 to 8 days |
| How it is given | Was given by daily subcutaneous injection (treatment) or intravenously (diagnostic test) | Subcutaneous injection in studies, weekly or less often; no approved product |
| U.S. regulatory status | Geref approvals withdrawn after 2008 discontinuation; 503B category 1 (under evaluation) | Never approved; on FDA's list of compounding substances that may present significant safety risks |
| Strongest human evidence | 1990s pediatric trials in GH deficiency (110 and 43 children) | Short placebo-controlled dose-escalation studies in healthy adults; Phase 2 trial terminated |
| Main safety concerns | Few modern data; compounded products only | FDA cites increased heart rate, systemic vasodilatory reactions, immunogenicity and impurities |
| WADA status (2026) | Prohibited at all times (S2, named) | Prohibited at all times (S2, named) |
Same Receptor, Very Different Duration
Natural GHRH is released in bursts, and growth hormone follows in pulses. A short-acting analogue gives a brief push; a long-acting one keeps stimulating the receptor continuously. Whether that difference matters for safety in people is not established.
Sermorelin (GHRH 1-29 amide)
Primary Target: Pituitary GHRH receptor
Affinity Profile: Agonist; short-acting native fragment
Gives a short GH rise after each injection. It increased growth rate in children with GH deficiency and raised GH and IGF-1 in older men over two weeks. GH release is still limited by somatostatin and IGF-1 feedback.
CJC-1295
Primary Targets: Pituitary GHRH receptor
Affinity Profile: Agonist; binds endogenous albumin after injection
In healthy adults one injection raised mean GH 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9 to 11 days. A study in healthy young men found GH pulses persisted, but trough (baseline) GH rose about 7.5-fold.
A Discontinued Medicine vs a Never-Approved Compound
Checked 11 October 2026 against Drugs@FDA, the Federal Register, FDA's 503B category list, FDA's compounding safety page and ClinicalTrials.gov.
Sermorelin Status & Formulations
Geref was approved in 1990 (NDA 019863, diagnostic) and 1997 (NDA 020443, pediatric growth failure). EMD Serono told FDA in 2008 that both were being discontinued; in 2013 FDA determined they were not withdrawn for safety or effectiveness reasons. No approved sermorelin product is marketed. Sermorelin acetate is in FDA's 503B category 1 (under evaluation); compounded sermorelin is not FDA-approved.
CJC-1295 Status & Formulations
No FDA-approved medicine contains CJC-1295. Its developer's Phase 2 trial is listed as terminated. FDA's compounding safety page says CJC-1295 may pose risks of immunogenicity and impurities, that serious adverse events including increased heart rate and systemic vasodilatory reaction have been identified, and that clinical data are limited.
Critical Regulatory Distinction
Sermorelin's past approval does not extend to compounded versions, and it says nothing about CJC-1295. Names used online may not match the molecule studied; the published human studies tested the long-acting albumin-binding version of CJC-1295.
Pediatric Trials vs Short Volunteer Studies
No trial has compared sermorelin with CJC-1295. Their studies involve different people and outcomes, so the results cannot be ranked.
Sermorelin: Sermorelin (1990s)
In a multicenter open-label study of 110 prepubertal children with GH deficiency (1996), mean growth velocity rose from about 4 to 8 cm per year at six months, without a control group. In a 43-child randomized comparison (1993), sermorelin increased growth but only growth hormone improved height relative to bone age. In older men, studies were tiny (10 and 11 men) and measured hormones over weeks; body composition did not change in the 11-man study.
CJC-1295: CJC-1295 (2006)
Two randomized, placebo-controlled, ascending-dose trials in healthy adults (28 and 49 days) found sustained, dose-dependent rises in GH and IGF-1 and no serious adverse reactions reported. A second study in healthy young men showed preserved GH pulses with markedly higher trough levels. A Phase 2 trial in people with HIV and abdominal fat (sponsor ConjuChem) was terminated, and no efficacy results were found in the registry or literature. No study has tested clinical outcomes such as body composition, strength or aging.
Limited Data for Both
Raising growth hormone and IGF-1 raises questions about glucose, fluid retention and cell growth. Neither peptide has modern long-term safety data, and CJC-1295's continuous stimulation adds an untested variable.
FDA safety concerns for CJC-1295
FDA lists CJC-1295 among bulk substances that may present significant safety risks in compounding. It reports serious adverse events including increased heart rate and systemic vasodilatory reactions, along with immunogenicity and impurity concerns, and notes that clinical data are limited.
| Safety Consideration | Sermorelin | CJC-1295 |
|---|---|---|
| Source of safety data | 1990s pediatric and small adult studies | Short volunteer studies; FDA adverse-event signals |
| Reported concerns | No excess bone-age advance or adverse lab changes in the 1996 pediatric study | Increased heart rate and systemic vasodilatory reactions (FDA) |
| Exposure pattern | Brief GH rise after each injection | GH and IGF-1 raised for days; trough GH markedly increased |
| Product quality | Compounded only; not FDA-approved | Unregulated 'research' products; identity and purity uncertain |
What Sermorelin and CJC-1295 Have in Common
Where the two compounds overlap in biology, evidence or regulatory context.
Same receptor
Both stimulate the pituitary GHRH receptor to release the body's own growth hormone.
No current approved product
Neither is available as an FDA-approved medicine in the U.S. today.
Banned in sport
WADA's 2026 list names both sermorelin and CJC-1295 in class S2.
Key Scientific & Clinical Differences
Meaningful distinctions in mechanism, strength of evidence, safety and regulatory status.
Duration
Sermorelin is short-acting; CJC-1295 binds albumin and acts for days.
Regulatory history
Sermorelin was approved and withdrawn for business reasons; CJC-1295 never got past Phase 2.
Evidence base
Sermorelin has pediatric efficacy trials; CJC-1295 has only hormone-level studies in healthy volunteers.
FDA safety flag
CJC-1295 is on FDA's compounding safety-risk list; sermorelin is in the 'under evaluation' category.
Scientific Comparison vs Clinical Recommendations
Inside Peptides compares scientific evidence, receptor pharmacology, and official regulatory documents to advance public and professional understanding. We do not determine which compound is appropriate for an individual patient, rank medications with arbitrary scores, or recommend initiating or switching treatments.
Decisions about any medicine require a licensed healthcare professional who can weigh personal medical history, contraindications, interactions and monitoring needs. Unapproved peptides have no established safe use, and products sold as “research chemicals” are not the preparations studied in clinical research.
Approved Uses vs Online Claims
A critical scientific distinction between verified, FDA-approved clinical uses and unverified claims circulating on social media and vendor platforms.
CJC-1295 is a longer-lasting, better sermorelin
Not supportedFDA has flagged CJC-1295 for serious adverse events; neither is an approved product today.
It lasts longer, but no study shows better clinical outcomes, and longer-lasting stimulation has not been shown to be safe. No trial has compared the two.
GHRH peptides reverse aging and build muscle
Not supportedNo GHRH analogue is FDA-approved for aging or muscle building.
Adult studies of both were small and short and measured hormone levels. An 11-man sermorelin study found no body-composition change.
Sermorelin is FDA-approved
Not supportedDrugs@FDA lists both Geref applications as discontinued.
It was approved as Geref, but both approvals were withdrawn after the 2008 discontinuation. Compounded sermorelin is not an approved product.
Evidence Strength Across Clinical Domains
Inside Peptides evaluates scientific certainty at the claim level. Because clinical evidence varies significantly depending on the therapeutic endpoint evaluated, each domain is assessed independently.
Pediatric GH deficiency
1990s trials support increased growth with sermorelin; CJC-1295 was not studied in children.
Raising GH and IGF-1 in adults
Small, short studies show hormone increases for both; this is not a clinical benefit.
Body composition, strength or aging
No adequate trial shows benefit for either.
Long-term safety
No modern long-term data; FDA has adverse-event concerns about CJC-1295.
What Research Still Doesn’t Tell Us
Identifying open scientific questions, pending active-comparator trials, and areas where long-term clinical data remain incomplete.
No direct comparison
No study has compared these two GHRH analogues.
Effects of continuous stimulation
Whether days-long GHRH stimulation is safe over months or years is unknown.
Why the CJC-1295 trial stopped
The registry gives no reason for termination, and no full results were found.
Product identity
Online products may not contain the molecule tested in published studies.
Related Compound Profiles
Individual profiles provide full molecular datasheets, CAS numbers, preclinical histories, and compound monographs.
Related Educational Resources
Scientific & Regulatory References
Every pharmacological mechanism, clinical trial result, and regulatory approval cited on this page is traceable to official FDA prescribing documentation, ClinicalTrials.gov registries, or peer-reviewed medical publications.
-
Multicenter open-label trial
Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.110 prepubertal children enrolled; no control group.
-
Randomized comparative trial
Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone.43 children; growth hormone itself performed better on height relative to bone age.
-
Randomized crossover study
Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.Hormone levels only, over 14 days.
-
Uncontrolled pilot study
Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.11 men, no placebo group.
-
Drug review
Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
-
FDA Drugs@FDA record
Drugs@FDA: GEREF (sermorelin acetate) injection, NDA 019863 (diagnostic product, discontinued)
-
FDA Drugs@FDA record
Drugs@FDA: GEREF (sermorelin acetate) injection, NDA 020443 (treatment product, discontinued)
-
Federal Register notice
Determination that GEREF (sermorelin acetate) injection products were not withdrawn from sale for reasons of safety or effectiveness
-
FDA compounding list
Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the FD&C Act (categories, updated March 21, 2025)Sermorelin acetate appears in category 1 (bulk drug substances under evaluation).
-
Two randomized placebo-controlled dose-escalation trials
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.Healthy adults aged 21-61; 28- and 49-day studies.
-
Clinical pharmacology study
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.Healthy men aged 20-40; one week after a single injection.
-
Registry Record
A Study to Evaluate CJC 1295 in HIV Patients With Visceral ObesityPhase 2, randomized, double-blind, placebo-controlled; status Terminated; 120 listed enrollment; sponsor ConjuChem. No reason for termination is given in the registry (checked 11 October 2026).
-
FDA safety page
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksCJC-1295 entry: immunogenicity and impurity concerns; serious adverse events including increased heart rate and systemic vasodilatory reaction; limited clinical data. Content current as of 22 April 2026.
-
Anti-doping rule
World Anti-Doping Code International Standard: Prohibited List 2026Section S2 lists GHRH and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin); S0 covers pharmacological substances with no current governmental approval for human therapeutic use.